L Citrome

Summary

Publications

  1. doi request reprint A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Postgrad Med 124:83-93. 2012
  2. doi request reprint Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Clin Schizophr Relat Psychoses 6:76-85. 2012
  3. doi request reprint Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    CNS Spectr 17:1-9. 2012
  4. doi request reprint Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    L Citrome
    New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 66:356-68. 2012
  5. doi request reprint Lurasidone in schizophrenia: new information about dosage and place in therapy
    Leslie Citrome
    Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 29:815-25. 2012
  6. doi request reprint A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1545-73. 2012
  7. doi request reprint On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1599-613. 2012
  8. doi request reprint Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Expert Opin Drug Metab Toxicol 8:873-88. 2012
  9. doi request reprint Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Int Clin Psychopharmacol 27:165-76. 2012
  10. doi request reprint Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder
    L Citrome
    New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 66:318-25. 2012

Detail Information

Publications36

  1. doi request reprint A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Postgrad Med 124:83-93. 2012
    ..To describe the efficacy, safety, and tolerability of duloxetine for the treatment of osteoarthritic pain...
  2. doi request reprint Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Clin Schizophr Relat Psychoses 6:76-85. 2012
    ..To describe the efficacy, safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat (NNT) and number needed to harm (NNH)...
  3. doi request reprint Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    CNS Spectr 17:1-9. 2012
    ..We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results...
  4. doi request reprint Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    L Citrome
    New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 66:356-68. 2012
    ..To describe the efficacy and safety of vilazodone for the treatment of major depressive disorder (MDD)...
  5. doi request reprint Lurasidone in schizophrenia: new information about dosage and place in therapy
    Leslie Citrome
    Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Adv Ther 29:815-25. 2012
    ..Additional studies are desirable to directly compare and contrast lurasidone's efficacy with other antipsychotic agents...
  6. doi request reprint A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1545-73. 2012
    ..Meta-analyses can overcome many of the limitations of individual studies, namely the power to detect differences, and help resolve the results of inconsistent studies...
  7. doi request reprint On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Pharmacother 13:1599-613. 2012
    ..The product label is commonly used as an authoritative source for drug information, especially for new medications that have a limited published evidence base. Key elements of the product label are descriptions of safety and tolerability...
  8. doi request reprint Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability
    Leslie Citrome
    New York Medical College, Valhalla, NY, USA
    Expert Opin Drug Metab Toxicol 8:873-88. 2012
    ..It is also approved for the treatment of adults with schizoaffective disorder, both as a monotherapy and as adjunctive therapy to mood stabilizers and/or antidepressants. Paliperidone is the active metabolite of risperidone...
  9. doi request reprint Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Int Clin Psychopharmacol 27:165-76. 2012
    ..All-cause discontinuation rates were higher for lurasidone versus risperidone. Long-term treatment with lurasidone was generally well tolerated in this study, with minimal effects on weight and metabolic outcomes...
  10. doi request reprint Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder
    L Citrome
    New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 66:318-25. 2012
    ..To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES)...
  11. doi request reprint Iloperidone: a clinical overview
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    J Clin Psychiatry 72:19-23. 2011
    ..Iloperidone may be best suited for patients who are sensitive to akathisia or who are unable to tolerate the sedation and weight gain that can occur more frequently with other antipsychotics...
  12. doi request reprint Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Clin Drug Investig 31:455-82. 2011
    ..Long-term weight management programmes have been shown to reduce weight gain in some patients...
  13. doi request reprint Drug safety evaluation of ziprasidone
    Leslie Citrome
    New York University School of Medicine, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA
    Expert Opin Drug Saf 10:437-48. 2011
    ..Similar to most second-generation antipsychotics, ziprasidone has a lower propensity for extrapyramidal side effects and hyperprolactinemia compared to first-generation antipsychotics...
  14. doi request reprint Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 65:330-40. 2011
    ..To describe the efficacy and safety of inhaled loxapine, a new formulation of an older antipsychotic being developed for the treatment of agitation associated with schizophrenia or bipolar disorder...
  15. doi request reprint Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, New York, NY, USA
    Postgrad Med 123:153-62. 2011
    ..Longer-term and naturalistic studies will be helpful in evaluating these agents and their role in the psychiatric armamentarium...
  16. doi request reprint Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 4:251-7. 2011
    ..Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval...
  17. doi request reprint Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 65:189-210. 2011
    ..To describe the efficacy and safety of lurasidone for the treatment of schizophrenia...
  18. doi request reprint Olanzapine-fluoxetine combination for the treatment of bipolar depression
    Leslie Citrome
    New York Medical College, 11 Medical Park Drive, Suite 106, Pomona, Valhalla, NY 10970, USA
    Expert Opin Pharmacother 12:2751-8. 2011
    ..Nonetheless, indirect comparisons indicate similar efficacy outcomes but different tolerability profiles, with quetiapine principally being associated with sedation. Additional approved treatment options would be welcome...
  19. doi request reprint Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials
    Leslie Citrome
    New York Medical College, Valhalla, New York, USA
    Hum Psychopharmacol 27:24-32. 2012
    ....
  20. doi request reprint Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis
    Leslie Citrome
    New York University School of Medicine, New York, NY, USA
    Schizophr Res 131:75-81. 2011
    ..We conducted a 5-factor analysis for evaluating the efficacy of iloperidone vs. placebo across these different domains in the treatment of schizophrenia...
  21. doi request reprint Pharmacological management of acute and persistent aggression in forensic psychiatry settings
    Leslie Citrome
    New York Medical College, Department of Psychiatry and Behavioral Sciences, Valhalla, USA
    CNS Drugs 25:1009-21. 2011
    ..Mood stabilizers such as valproate may be helpful in instances of poor impulsivity and personality disorders. Other agents that have been successfully used include β-adrenoceptor antagonists (β-blockers) and antidepressants...
  22. ncbi request reprint Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns
    J Volavka
    New York University, Department of Psychiatry, Nathan Kline Institue for Psychiatric Research, Orangeburg 10962, USA
    Schizophr Res 35:S23-33. 1999
    ..g. randomization) used in typical designs of psychopharmacological clinical trials. Current research methods should be modified and new ones developed in order to progress in assessing the antiaggressive effects of treatments...
  23. doi request reprint Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic
    L Citrome
    Department of Psychiatry, New York University School of Medicine and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Int J Clin Pract 64:707-18. 2010
    ..To describe the contents of a Drug Approval Package and to describe the efficacy and safety of iloperidone for the treatment of schizophrenia...
  24. doi request reprint Compelling or irrelevant? Using number needed to treat can help decide
    L Citrome
    Department of Psychiatry, New York University School of Medicine, The Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 117:412-9. 2008
    ....
  25. doi request reprint Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic
    L Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Int J Clin Pract 63:1237-48. 2009
    ..The aim of the study was to describe the efficacy and safety of iloperidone for the treatment of schizophrenia...
  26. doi request reprint Heterogeneity of violence in schizophrenia and implications for long-term treatment
    J Volavka
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 62:1237-45. 2008
    ..The aim of this review is to address the subtyping of violent behaviour in schizophrenia, and to relate the subtypes to treatment...
  27. doi request reprint Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
    T A Ketter
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Acta Psychiatr Scand 123:175-89. 2011
    ..To compare bipolar treatment interventions, using number needed to treat (NNT) and number needed to harm (NNH)...
  28. ncbi request reprint Paliperidone: quo vadis?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Int J Clin Pract 61:653-62. 2007
    ..With the impending availability of oral risperidone as a generic medication, cost of oral paliperidone will likely become a significant obstacle to its use...
  29. ncbi request reprint Violent patients in the emergency setting
    L Citrome
    Department of Psychiatry, New York University, New York, USA
    Psychiatr Clin North Am 22:789-801. 1999
    ..The use of typical neuroleptics may lead to side effects, such as akathisia, which may in turn precipitate additional agitation. This may be obviated with the introduction of IM preparations of atypical antipsychotics...
  30. doi request reprint Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 63:1762-84. 2009
    ..To describe the efficacy and safety of asenapine for the treatment of schizophrenia and bipolar disorder...
  31. doi request reprint Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia
    L Citrome
    New York University School of Medicine, Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Int J Clin Pract 62:837-40. 2008
  32. doi request reprint Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic
    L Citrome
    New York University School of Medicine, Department of Psychiatry, NY, USA
    Int J Clin Pract 63:140-50. 2009
    ..07% of injections, requiring patients to be observed for 3 h after injection. At present, there are no studies available that directly compare olanzapine pamoate with other antipsychotics other than oral olanzapine...
  33. doi request reprint Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 64:216-39. 2010
    ..To describe the efficacy, safety and cost of paliperidone palmitate, a depot antipsychotic medication recently approved for the treatment of schizophrenia...
  34. doi request reprint When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    L Citrome
    Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
    Int J Clin Pract 67:407-11. 2013
    ..Additional considerations in interpreting NNT are discussed, including the importance of defining acceptable response, adverse outcomes of interest, the effect of time, and the importance of individual baseline characteristics...
  35. doi request reprint Relative vs. absolute measures of benefit and risk: what's the difference?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 121:94-102. 2010
    ..When appraising evidence clinicians are confronted with two types of comparisons: ratios, such as relative risk, and absolute differences, such as number needed to treat (NNT) or number needed to harm (NNH)...
  36. ncbi request reprint Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 60:933-40. 2006
    ..NNT and NNH can help place the wide array of CATIE results into clinical context, and permits quantification of the differences observed between the antipsychotics that were tested...